RIGEL PHARMACEUTICALS INC

RIGL is the ticker symbol for RIGEL PHARMACEUTICALS INC, a publicly traded US company.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Key metrics include a return on equity of 2.2%, a debt-to-equity ratio of 0.26.

The company reports trailing twelve-month revenue of $58.82M and net income of $8.65M.

FINOTAUR aggregates real-time and fundamental data on RIGL to help traders and investors make informed decisions. Track RIGL in your trading journal alongside other positions for a unified view of your portfolio.